← Leaderboards
Carrie Danielle House
San Diego State University
$3,947,730
Attributed
$3,947,730
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $651.6K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,947,730 · 3
By mechanism
R01$1,622,419 · 1
U54$1,464,403 · 1
R00$860,908 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “United States”
- Leonard Freedman · Leidos Biomedical Research, Inc.$818,172,357
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$284,203,793
- Chanza Baytop · Westat, Inc.$271,217,917
Research focus
United StatesCellsResistanceTumorDrug ResistanceNf-Kappa BRelapsePathway InteractionsSignal TransductionTranscription FactorMalignant Female Reproductive System NeoplasmCancer RelapseMortalityMouse ModelMediatingMalignant Neoplasm Of OvaryChemotherapyCancer CellSignal PathwayGenesMorbidity - Disease RatePlayRecurrenceOvarian Neoplasm
Grant awards (16)
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse$345,771
R01 · FY2025 · CA · contact PI
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse$87,191
R01 · FY2025 · CA · contact PI
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse$339,552
R01 · FY2024 · CA · contact PI
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse$82,831
R01 · FY2024 · CA · contact PI
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse$11,826
R01 · FY2024 · CA · contact PI
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse$387,223
R01 · FY2023 · CA · contact PI
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse$368,025
R01 · FY2022 · CA · contact PI
Research Project-Obesity in Cancer: The role of obesity in NF-kB-induced cancer stem cell-like phenotype and its implication in ovarian cancer tumorigenesis and chemoresistance$272,095
U54 · FY2022 · MD · contact PI
Research Project-Obesity in Cancer: The role of obesity in NF-kB-induced cancer stem cell-like phenotype and its implication in ovarian cancer tumorigenesis and chemoresistance$277,400
U54 · FY2021 · MD · contact PI
Role of NF-kB signaling in supporting ovarian cancer tumor-initiating cells responsible for cancer recurrence$311,879
R00 · FY2020 · CA · contact PI
Research Project-Obesity in Cancer: The role of obesity in NF-kB-induced cancer stem cell-like phenotype and its implication in ovarian cancer tumorigenesis and chemoresistance$288,688
U54 · FY2020 · MD · contact PI
Role of NF-kB signaling in supporting ovarian cancer tumor-initiating cells responsible for cancer recurrence$51,029
R00 · FY2020 · CA · contact PI
Research Project-Obesity in Cancer: The role of obesity in NF-kB-induced cancer stem cell-like phenotype and its implication in ovarian cancer tumorigenesis and chemoresistance$295,332
U54 · FY2019 · MD · contact PI
Role of NF-kB signaling in supporting ovarian cancer tumor-initiating cells responsible for cancer recurrence$249,000
R00 · FY2019 · CA · contact PI
Research Project-Obesity in Cancer: The role of obesity in NF-kB-induced cancer stem cell-like phenotype and its implication in ovarian cancer tumorigenesis and chemoresistance$330,888
U54 · FY2018 · MD · contact PI
Role of NF-kB signaling in supporting ovarian cancer tumor-initiating cells responsible for cancer recurrence$249,000
R00 · FY2018 · CA · contact PI